- Home
- MTRX vs IVA Comparison
MTRX vs IVA Comparison
Compare MTRX & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTRX
- IVA
- Stock Information
- Founded
- MTRX 1984
- IVA 2011
- Country
- MTRX United States
- IVA France
- Employees
- MTRX N/A
- IVA N/A
- Industry
- MTRX Engineering & Construction
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- MTRX Consumer Discretionary
- IVA Health Care
- Exchange
- MTRX Nasdaq
- IVA Nasdaq
- Market Cap
- MTRX 327.8M
- IVA 359.6M
- IPO Year
- MTRX 1990
- IVA 2020
- Fundamental
- Price
- MTRX $12.97
- IVA $3.58
- Analyst Decision
- MTRX Strong Buy
- IVA Strong Buy
- Analyst Count
- MTRX 1
- IVA 4
- Target Price
- MTRX $20.00
- IVA $10.50
- AVG Volume (30 Days)
- MTRX 218.5K
- IVA 18.0K
- Earning Date
- MTRX 05-07-2025
- IVA 03-26-2025
- Dividend Yield
- MTRX N/A
- IVA N/A
- EPS Growth
- MTRX N/A
- IVA N/A
- EPS
- MTRX N/A
- IVA N/A
- Revenue
- MTRX $742,408,000.00
- IVA $14,591,573.00
- Revenue This Year
- MTRX $19.64
- IVA $15.38
- Revenue Next Year
- MTRX $23.51
- IVA $24.22
- P/E Ratio
- MTRX N/A
- IVA N/A
- Revenue Growth
- MTRX N/A
- IVA N/A
- 52 Week Low
- MTRX $8.61
- IVA $1.53
- 52 Week High
- MTRX $15.75
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- MTRX 58.52
- IVA 54.47
- Support Level
- MTRX $10.01
- IVA $3.48
- Resistance Level
- MTRX $13.80
- IVA $3.77
- Average True Range (ATR)
- MTRX 0.94
- IVA 0.22
- MACD
- MTRX 0.19
- IVA -0.03
- Stochastic Oscillator
- MTRX 78.16
- IVA 48.68
About MTRX Matrix Service Company
Matrix Service Co is an engineering and construction provider for large industrial projects, primarily in the oil and gas, power, petrochemical, industrial, mining, and minerals markets. It offers engineering, fabrication, construction, and maintenance services, operating across three segments namely Utility and Power Infrastructure; Process and Industrial Facilities; and Storage and Terminal Solutions.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.